The opportunity for an Oral Preventative Treatment for Hypoglycemia is just one of many areas of high unmet medical need associated with Metabolic Disorders. We are committed to addressing this.
The highest unmet need in the Diabetes space is the inability to maintain good long term glycemic control. By 2040 it is estimated that 625 million people will be suffering from Diabetes. One of the biggest fears in a significant percentage of Diabetes patients is hypoglycemia and the associated risks including death. Hypoglycemia affects over 100 million patients of Type 1 and Type 2 Diabetes including a significant pediatric population. We are committed to providing a prevention with meaningful long term benefit.
Driven by Opportunity
Global Healthcare Expenditures of Diabetes is expected to reach $490 Billion by 2030, with 537 million current patients needing a Hypoglycemia prevention right now. Our Team is focused on providing meaningful therapies for patients suffering from Diabetes and associated metabolic disorders.